Edition:
United States

Amarin Corporation PLC (AMRN.O)

AMRN.O on Consolidated Issue listed on NASDAQ Global Market

3.22USD
19 Sep 2017
Change (% chg)

-- (--)
Prev Close
$3.22
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,233,726
52-wk High
$4.47
52-wk Low
$2.56

Chart for

About

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule,... (more)

Overall

Beta: 0.67
Market Cap(Mil.): $880.07
Shares Outstanding(Mil.): 270.79
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 80.15 16.18
EPS (TTM): -- -- --
ROI: -- 3.01 14.60
ROE: -- 4.76 13.87

BRIEF-Amarin names Mark Salyer chief commercial officer

* Amarin appoints Mark W. Salyer to new position of chief commercial officer

Sep 13 2017

BRIEF-Amarin's reduce-it cardiovascular outcomes study of Vascepa to continue as planned

* Amarin's reduce-it cardiovascular outcomes study of Vascepa to continue as planned at recommendation of independent data monitoring committee

Aug 14 2017

BRIEF-Amarin reports Q2 loss per share $0.05

* Amarin reports second quarter 2017 financial results and provides update on operations

Aug 02 2017

BRIEF-Amarin says vascepa showed reductions in potentially atherogenic lipid parameters

* Amarin says vascepa showed reductions in potentially atherogenic lipid parameters in statin-treated women with type 2 diabetes and persistent high triglycerides

Jun 12 2017

BRIEF-Amarin Q1 loss per share $0.08

* Amarin reports first quarter 2017 financial results and provides update on operations

May 03 2017

Earnings vs. Estimates